Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

risdiplam

Roche - Basel

Roche makes $1.7bn oncology acquisition

Takes over Seragon and its pipeline of investigational breast cancer treatments

- PMLiVE

Erbitux betters Avastin in bowel cancer subgroup

Data backs Merck KGaA drug over Roche’s rival in RAS wild-type metastatic colorectal cancer

- PMLiVE

Avastin first biologic backed in EU for resistant ovarian cancer

Roche drug recommended in latest round of CHMP opinions

- PMLiVE

AbbVie, Astellas and Roche teams among Communiqué finalists

2014 shortlist also includes MHP, Pegasus, Red Door, Ruder Finn and Virgo

Roche - Basel

CHMP turns down Avastin for brain cancer

Roche set to be denied expanded use for oncology drug in Europe

- PMLiVE

CHMP backs European approval for six new medicines

Recommends drugs by PTC Therapeutics, Roche, Biogen Idec, Octapharma, Alcon and Veloxis Pharma

China flag thumb

Roche drawn into Chinese probe into pharma

State authorities visit regional offices of Swiss company

Roche - Basel

Roche and Merck boost manufacturing capacity

Pharma companies invest in European facilities

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

- PMLiVE

EMA warns on stolen Herceptin

Says vials of cancer drug have been tampered with and re-introduced into supply chain

- PMLiVE

Integrating multichannel marketing

External forces are driving the need for pharma to use a greater variety of channels to reach customers

- PMLiVE

Herceptin could face biosimilars in UK later this year

Court overturns patents protecting Roche’s cancer drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links